Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model

Experimental Neurology

Volumn 204, Issue 1, 2007, Pages 260-263

  Grunfeld, Jonathan F ^a   Barhum, Yael ^b   Blondheim, Netta ^b   Rabey, Jose Martin ^a   Melamed, Eldad ^b   Offen, Daniel ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Amyotrophic lateral sclerosis; Animal model; Erythropoietin; Neuroprotection

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; FATALITY; FEMALE; GENDER; IMMUNOSTIMULATION; MALE; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENIC MOUSE;

ADENINE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GUANINE; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR NEURONS; MUTATION; NEUROPROTECTIVE AGENTS; SEX FACTORS; SPINAL CORD; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 33847687265     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.11.002     Document Type: Article

References (20)

1. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev., Neurosci. 6 (2005) 484-494
2. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10526-10531
3. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749
4. Carri M.T., Ferri A., Cozzolino M., Calabrese L., and Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res. Bull. 61 (2003) 365-374
5. Celik M., Gokmen N., Erbayraktar S., Akhisaroglu M., Konakc S., Ulukus C., Genc S., Genc K., Sagiroglu E., Cerami A., and Brines M. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2258-2263
6. del Aguila M.A., Longstreth W.T., McGuire V., Koepsell T.D., and van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60 (2003) 813-819
7. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
8. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.W., Coleman T., Kreilgaard M., Torup L., Sager T., Erbayraktar Z., Gokmen N., Yilmaz O., Ghezzi P., Villa P., Fratelli M., Casagrande S., Leist M., Helboe L., Gerwein J., Christensen S., Geist M.A., Pedersen L.O., Cerami-Hand C., Wuerth J.P., Cerami A., and Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6741-6746
9. Farooque M., Suo Z., Arnold P.M., Wulser M.J., Chou C.T., Vancura R.W., Fowler S., and Festoff B.W. Gender-related differences in recovery of locomotor function after spinal cord injury in mice. Spinal Cord 44 (2006) 182-187
10. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
11. Haverkamp L.J., Appel V., and Appel S.H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118 Pt 3 (1995) 707-719
12. Incidence of ALS in Italy: evidence for a uniform frequency in Western countries. Neurology 56 (2001) 239-244
13. Jelkmann W. Erythropoietin. J. Endocrinol. Invest. 26 (2003) 832-837
14. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
15. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., and Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
16. Li H., Pin S., Zeng Z., Wang M.M., Andreasson K.A., and McCullough L.D. Sex differences in cell death. Ann. Neurol. 58 (2005) 317-321
17. Sejvar J.J., Holman R.C., Bresee J.S., Kochanek K.D., and Schonberger L.B. Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 25 (2005) 144-152
18. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4044-4049
19. Sowade B., Sowade O., Mocks J., Franke W., and Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int. J. Mol. Med. 1 (1998) 303-314
20. Veldink J.H., Bar P.R., Joosten E.A., Otten M., Wokke J.H., and van den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 13 (2003) 737-743